Figure 2.

Box (median and 25th–75th percentiles) and whiskers (5th–95th percentiles) plot of posaconazole trough concentrations (C _min) following administration of posaconazole tablets in hematologic patients receiving no interacting co‐treatments (Controls; 34 observations in 20 patients), in those receiving proton pump inhibitors (PPIs; 113 observations in 43 patients), in those receiving intermediate or high dose steroids (>0.7 mg kg⁻¹ daily) (Steroids; 9 observations in 5 patients) and in those receiving proton pump inhibitors plus intermediate or high dose steroids (PPIs+ steroids; 20 observations in 13 patients). The dashed line identifies posaconazole target levels for prophylaxis (C _min > 0.7 mg l⁻¹) of fungal infections. A P‐value < 0.001 was obtained at Kruskal–Wallis test. A significant difference after post‐hoc Bonferroni correction was observed between Controls and PPIs (P < 0.001), Controls and Steroids (P = 0.003) and Controls and PPIs+ Steroids (P < 0.001)